Clinical trials: Chronic Obstructive Pulmonary
Psoriasis
A Study To Evaluate The Effects And Safety Of Treatment, Treatment Withdrawal, Followed By Re-Treatment With CP-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis
The primary objectives of the study are to 1) compare the efficacy responses of CP 690,550 (5 mg BID and 10 mg BID) versus placebo following 24 weeks of CP 690,550 treatment and subsequent withdrawal of active treatment at…
- Trial name
- NCT01186744
- Testing
- CP-690,550
- Where
- 87 sites in United States, Argentina and 10 more
- Volunteers
- 666 people
- Sponsor
- Pfizer
Chronic Obstructive Pulmonary Disease (COPD)
Study Evaluating Preference, Satisfaction and Ease of Use of Inhalers in Chronic Obstructive Pulmonary Disease (COPD) Diagnosed Patients
Preference study: Genuair vs HandiHaler inhalers in COPD patients.
- Trial name
- NCT01385696
- Testing
- Genuair® (Almirall S.A.), HandiHaler® (Boehringer Ingelheim's)
- Where
- 4 sites in Germany, Netherlands
- Volunteers
- 130 people
- Sponsor
- Almirall, S.A.
Asthma, Coronary Artery Disease
A Study of the Safety and Tolerance of Regadenoson in Subjects With Asthma or Chronic Obstructive Pulmonary Disease
This study is intended to determine the safety and tolerance of regadenoson in subjects with asthma or chronic obstructive pulmonary disease.
- Conditions
- Asthma, Coronary Artery Disease, Pulmonary Disease, Chronic Obstructive
- Trial name
- NCT00862641
- Testing
- Regadenoson
- Where
- 48 sites in United States
- Volunteers
- 1,009 people
- Sponsor
- Astellas Pharma Inc
Pulmonary Disease, Chronic Obstructive
Actuation Indicator Trial in Patients With COPD
The primary objective of this study is to evaluate the performance, accuracy, and handling of the actuation indicator in patients with COPD.
- Trial name
- NCT00928746
- Testing
- Ipratropium bromide
- Where
- 7 sites in United States
- Volunteers
- 142 people
- Sponsor
- Boehringer Ingelheim
Graft Versus Host Disease
Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Chronic Graft Versus Host Disease
The purpose of this study is to assess the safety and clinical efficacy of ibrutinib in subjects with steroid dependent or refractory Chronic Graft Versus Host Disease.
- Trial name
- NCT02195869
- Testing
- Ibrutinib
- Where
- 10 sites in United States
- Volunteers
- 45 people
- Sponsor
- Pharmacyclics LLC.
Smoking, Pulmonary Disease, Chronic Obstructive
Smoking Cessation Versus Long-term Nicotine Replacement Among High-risk Smokers
Long-term NRT has not been studied in patients with COPD, and smokers in the United States with COPD are still asked to choose between immediate quitting or continued smoking.
- Conditions
- Smoking, Pulmonary Disease, Chronic Obstructive, Tobacco Use Disorder
- Trial name
- NCT02148445
- Testing
- Standard Smoking Cessation, Extended Nicotine Replacement Therapy, Nicotine replacement therapy
- Where
- United States
- Volunteers
- 398 people
- Sponsor
- University of Kansas Medical Center
Chronic Spontaneous Urticaria
A Safety Extension Study to Evaluate the Long-term Safety of QGE031 in Chronic Spontaneous Urticaria (CSU) Patients
A safety extension study to evaluate the long-term safety of QGE031 240 mg s.c. given every 4 weeks for 52 weeks in Chronic Spontaneous Urticaria (CSU) patients who completed study CQGE031C2201
- Trial name
- NCT02649218
- Testing
- Ligelizumab
- Where
- 67 sites in United States, Australia and 8 more
- Volunteers
- 226 people
- Sponsor
- Novartis Pharmaceuticals
Thyroid Eye Disease, Chronic (Inactive) Thyroid Eye Disease
A Study Evaluating TEPEZZA® Treatment in Patients With Chronic (Inactive) Thyroid Eye Disease
The overall objective is to investigate the efficacy, safety and tolerability of TEPEZZA® in participants with chronic (inactive) TED (thyroid eye disease). Approximately 57 participants will be enrolled.
- Trial name
- NCT04583735
- Testing
- TEPEZZA
- Where
- 12 sites in United States
- Volunteers
- 62 people
- Sponsor
- Amgen
Chronic Fatigue Syndrome
Use of Xyrem to Improve Sleep in Chronic Fatigue Syndrome
Chronic fatigue syndrome is a disabling illness for which there is no specific treatment. As a group, CFS patients have disturbed sleep with frequent arousals and the sense of not having slept upon awakening.
- Trial name
- NCT00498485
- Testing
- Sodium Oxybate
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of Medicine and Dentistry of New Jersey
Pulmonary Disease, Chronic Obstructive
Absorption & Elimination of Radiolabelled GSK2269557
GSK2269557 is being developed as an anti-inflammatory agent for the treatment of chronic obstructive pulmonary disease (COPD) and other inflammatory lung diseases such as asthma.
- Trial name
- NCT03315559
- Testing
- [14C]-GSK2269557 IV infusion, GSK2269557 via DPI, [14C]-GSK2269557 oral solution
- Where
- United Kingdom
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease
Study to Assess the Lung Exposure Bioequivalence of Budesonide, Glycopyrronium, and Formoterol Delivered by BGF MDI With Next-Generation Propellant Compared With BGF MDI With HFA Propellant
The study will assess the Pharmacokinetic (PK) and safety of BGF MDI [Budesonide/glycopyrronium/formoterol (BGF) metered dose inhaler (MDI)] formulated with 2 different propellants :Hydrofluoroolefin (HFO) and Hydrofluoroalkane…
- Trial name
- NCT05477108
- Testing
- Treatment A (BGF MDI HFO with oral activated charcoal), Treatment B (BGF MDI HFA with oral activated charcoal)
- Where
- United States
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease (COPD)
A Study to Assess Drug Absorption of Fixed Dose Combinations of Budesonide, Glycopyrronium, and Formoterol
The study will evaluate bioavailability, pharmacokinetics, safety, and tolerability of budesonide, glycopyrronium and formoterol (BGF) metered dose inhaler (MDI) formulated with 3 different propellants: Propellant 1 (Treatment A…
- Trial name
- NCT04600505
- Testing
- Treatment A, Treatment B, Treatment C
- Where
- United States
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease
Efficacy and Safety Study of QVA149 in COPD Patients
The purpose of this study is to demonstrate that the efficacy of the combination product QVA149 is similar to the efficacy of the combination product umeclidinium/vilanterol on a pre-specified endpoint of FEV1 AUC0-24h while…
- Trial name
- NCT02487446
- Testing
- QVA149, Umeclidinium/vilanterol
- Where
- 58 sites in United States
- Volunteers
- 357 people
- Sponsor
- Novartis Pharmaceuticals
Pulmonary Disease, Chronic Obstructive
A Trial Comparing Treatment With Tiotropium Inhalation Capsules to Combivent Inhalation Aerosol in COPD Patients.
The objective of this study is to evaluate the efficacy and safety of 12 weeks treatment with tiotropium HandiHaler 18 micrograms (mcg) daily compared to Combivent Metered Dose Inhaler (MDI) Chlorofluorocarbon Inhalation Aerosol…
- Trial name
- NCT00359788
- Testing
- tiotropium, Combivent (Ipratropium/Albuterol)
- Where
- 31 sites in United States
- Volunteers
- 349 people
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease (COPD)
Efficacy and Safety of Indacaterol Plus Tiotropium Versus Tiotropium Alone in Patients With Chronic Obstructive Pulmonary Disease
This study assessed the efficacy and safety of indacaterol (150 µg once daily [od]) when combined with tiotropium (18 µg od) versus tiotropium (18 µg od) treatment alone in patients with chronic obstructive pulmonary disease…
- Trial name
- INTRUST2 (NCT00877383)
- Testing
- Indacaterol 150 μg, Tiotropium 18 μg
- Where
- 176 sites in United States, Canada and 7 more
- Volunteers
- 1,142 people
- Sponsor
- Novartis Pharmaceuticals
COPD, Emphysema
Bronchitis and Emphysema Advice and Training to Reduce Hospitalization
EXECUTIVE SUMMARY: Purpose: To evaluate the efficacy and cost-effectiveness of a novel intervention incorporating self-management education, an action plan, and case-management to decrease the risk of hospitalizations due to…
- Trial name
- BREATH (NCT00395083)
- Testing
- COPD Self-management Education
- Where
- 22 sites in United States
- Volunteers
- 426 people
- Sponsor
- US Department of Veterans Affairs
COPD, Pulmonary Disease, Chronic Obstructive
The Trajectory of Physical Activity Following Pulmonary Rehabilitation
Pulmonary rehabilitation clearly increases exercise capacity, but its effect on physical activity in the home and community settings is less clear. It may take a longer time for this increase in physical activity to occur.
- Trial name
- NCT02399254
- Where
- 4 sites in United States
- Volunteers
- 21 people
- Sponsor
- Trinity Health Of New England
Pulmonary Disease, Chronic Obstructive
A Study to Assess the Efficacy of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25 mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50 mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
This will be a Phase IIIb multicentre, randomized, double-blind, double-dummy, 12-week parallel group study evaluating the effects of once daily in the morning treatment of FF/VI Inhalation Powder versus Fluticasone…
- Trial name
- NCT01706328
- Testing
- FF/VI 100/25 Inhalation Powder NDPI, Fluticasone Propionate/Salmeterol 250/50 Inhalation Powder ACCUHALER/DISKUS, Salbutamol as needed
- Where
- 63 sites in United States, Germany and 3 more
- Volunteers
- 828 people
- Sponsor
- GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
28-day Repeat Dose Study of GSK573719
The study will evaluate the efficacy, safety, and pharmacokinetics of GSK573719 compared with placebo in subjects with COPD
- Trial name
- NCT01030965
- Testing
- GSK573719 125mcg, GSK573719 250mcg, GSK573719 500mcg
- Where
- 20 sites in United States, Estonia and 2 more
- Volunteers
- 285 people
- Sponsor
- GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
Tiotropium Respimat Pharmacokinetic Study in COPD
The purpose of this study is compare the effect of different doses of tiotropium delivered by the HandiHaler and Respimat device on lung function.
- Trial name
- NCT01222533
- Testing
- Tiotropium medium, Tiotropium low, Tiotropium high
- Where
- 11 sites in Belgium, Denmark and 3 more
- Volunteers
- 154 people
- Sponsor
- Boehringer Ingelheim
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.